Latest Insights | BiopharmaTrend

When Agents Run Computations: Schrödinger’s Robert Abel On Where The Human Still Decides

Generating drug candidate ideas has become inexpensive, and the supply of hypotheses now exceeds any organization’s capacity to evaluate them. Schrödinger’s answer, launched at the end of July, is Bunsen: …

Continue ›››

WhiteLab Genomics Raises $26M to Scale AI-designed Delivery Systems for Cell and Gene Therapies

Techbio company WhiteLab Genomics has raised a $26 million Series B to develop and license its own AI-designed gene delivery technologies, moving beyond the computational services business it started with. …

Continue ›››

Is “Rescuing Failed Drugs with AI” a Category Now?

Inside the growing bet that AI can find the patients pharma's failed trials missed... Update (October 2026): Five months after this piece was first published, Biossil raised another $153 million …

Continue ›››

The $2.7B Question: How Do We Know If Isomorphic's AI Works?

Isomorphic Labs has raised about $2.7 billion from outside investors since 2025. Its president, Max Jaderberg, says its drug design engine works, but the company has not publicly named a …

Continue ›››

Biotech IPOs Roar Back, With Nvidia-Backed Iambic Next in Line

Recently, Iambic Therapeutics has filed to go public on Nasdaq under the ticker IAM, adding another closely watched name to a biotech IPO market that has begun to reopen after …

Continue ›››

Three AI Drug Discovery Startups Raise $526 Million in Two Days

Three AI drug discovery companies raised a combined $526 million on September 23 and 24. One mines plants and microbes for new medicines. One trains its models on what it …

Continue ›››

Big Pharma Is Betting On LLMs and Agents. What Would Count As Success?

In the latest news, Novo Nordisk has entered a collaboration with Anthropic aimed at speeding the discovery and development of new medicines. An initial project will test Anthropic's Claude Science …

Continue ›››

The Bigger Point Beyond Insilico's Aging Research Milestone

This week Insilico Medicine, an AI-driven drug discovery company, reported an unusual experiment. Arguably for the first time, aging biomarkers were written prospectively into a controlled trial run for a …

Continue ›››

The Measurement Challenge in Longevity: Can Aging Biomarkers and Clocks Close the Gap?

An article published in Nature Biotechnology on 7 September 2026 by Alex Zhavoronkov’s team at Insilico Medicine and collaborators marks an important step forward for the field of drugs targeting …

Continue ›››

What Do the New AI Model Releases by Anthropic and OpenAI Change for Life Sciences?

Last week, Anthropic and OpenAI released new frontier models, specifically, Anthropic shipped Claude Fable 5.1 and a restricted variant called Mythos 5.1, while OpenAI shipped GPT-6 Astra. OpenAI president, Greg …

Continue ›››

Into the Dark: Finding Novel Drug Targets Within the Depths of Our Proteome

Drug discovery has never had a richer therapeutic toolbox. Antibody-drug conjugates, antisense oligonucleotides, CRISPR therapeutics, RNA medicines, CAR-T cells, PROTACs, and molecular glues have transformed how medicine can manipulate biology. …

Continue ›››

Beyond the Code: How DNA Nanotechnology is Moving from Molecular Origami to Programmable Biotech Platforms

Biotech treats DNA primarily as a coding material that provides information about disease phenotypes and can serve as a drug target and modality. But beyond the code, DNA is also …

Continue ›››